FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 125 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 ‘Being open will help bring awareness’: Meet the fashion vlogger who... November 16, 2022 Veteran and His Loyal Dog Pass Away Within Hours Of Each... May 21, 2020 In Memory of Håkan Mellstedt: Former ESMO President August 26, 2025 Load more HOT NEWS A New Study Suggests Screen Time Might Not Be The Worst... ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ News digest – dinosaur bone cancer, YouTube junk food ad ban... Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian...
